Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp. has partnered with Siemens Healthineers to enhance access to the TULSA Procedure, an incision-free therapy for ablating diseased prostate tissue using real-time MR guidance. The collaboration will integrate Profound’s TULSA-PRO system with Siemens’ MAGNETOM Free.Max MRI scanner, providing a comprehensive therapeutics solution. This partnership aims to streamline the treatment process, potentially allowing patients to be diagnosed and treated on the same day.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
